Alivus Life Sciences Ltd vs Procter Gamble Health Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: May 06, 2026

Key Highlights

The Latest Trading Price of Alivus Life Sciences Ltd is ₹ 1046 as of 13 Apr 15:30 . The p/e ratio of Alivus Life Sciences Ltd changed from 27.2 to 20.2 over 5 quarters. This represents a CAGR of -21.18% The p/e ratio of Procter & Gamble Health Ltd changed from 52.5 to 0 over 9 quarters. This represents a CAGR of -100.00% The market cap of Alivus Life Sciences Ltd changed from ₹ 13229 crore to ₹ 9499 crore over 5 quarters. This represents a CAGR of -23.27% The market cap of Procter & Gamble Health Ltd changed from ₹ 9285 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The revenue of Alivus Life Sciences Ltd for the Dec '25 is ₹ 686.82 crore as compare to the Sep '25 revenue of ₹ 602.7 crore. This represent the growth of 13.96% The revenue of Procter & Gamble Health Ltd for the Dec '25 is ₹ 378.22 crore as compare to the Sep '25 revenue of ₹ 329.87 crore. This represent the growth of 14.66% The ebitda of Alivus Life Sciences Ltd for the Dec '25 is ₹ 219.54 crore as compare to the Sep '25 ebitda of ₹ 193.89 crore. This represent the growth of 13.23% The ebitda of Procter & Gamble Health Ltd for the Dec '25 is ₹ 114.82 crore as compare to the Sep '25 ebitda of ₹ 125.22 crore. This represent the decline of -8.31% The net profit of Alivus Life Sciences Ltd changed from ₹ 136.96 crore to ₹ 150.26 crore over 7 quarters. This represents a CAGR of 5.44% The net profit of Procter & Gamble Health Ltd changed from ₹ 46.56 crore to ₹ 77.59 crore over 7 quarters. This represents a CAGR of 33.89% The dividend payout of Alivus Life Sciences Ltd changed from 12.62 % to 58.56 % over 5 quarters. This represents a CAGR of 241.38% The dividend payout of Procter & Gamble Health Ltd changed from 122.06 % to 0 % over 9 quarters. This represents a CAGR of -100.00% .

About Alivus Life Sciences Ltd

Alivus Life Sciences Limited was initially established as 'Zorg Laboratories Private Limited', on June 23, 2011 and was granted the Certificate of Incorporation by the Registrar of Companies, Maharashtra in Pune.
Subsequently, the Company was acquired by Glenmark Pharmaceuticals Limited through a Share Purchase Agreement dated 04 July 2018 and the name of the Company was changed to Glenmark Life Sciences Private Limited' and a fresh Certificate of Incorporation dated 28 August 2018 was issued by the RoC. The name of the Company has now changed to 'Alivus Life Sciences Limited' on January 20, 2025. Nirma Limited is a Subsidiary of the Company.
The Company is engaged in the business of development, manufacture and marketing of Active Pharmaceutical Ingredients(APIs). In 2001, Glenmark Pharmaceuticals established its API business.

About Procter & Gamble Health Ltd

Procter & Gamble Health Limited was erstwhile incorporated as E Merck (India) Limited in 1967.
The Company's name was changed from E Merck (India) Limited to Merck Limited on March 27, 2002.
Later, the name of the Company was changed to Procter & Gamble Health Limited on 6 May, 2019.
The company was set up to take over the business of the Indian branch of Emeda Exports with all their assets and liabilities.
The company is a 51% subsidiary of German firm Merck KGaA, is a leading player in vitamin formulations. Procter & Gamble Health Limited is an Indian-based company principally engaged in the business of manufacturing and marketing of pharmaceuticals and chemicals.

FAQs for the comparison of Alivus Life Sciences Ltd and Procter & Gamble Health Ltd

Which company has a larger market capitalization, Alivus Life Sciences Ltd or Procter & Gamble Health Ltd?

Market cap of Alivus Life Sciences Ltd is 13,788 Cr while Market cap of Procter & Gamble Health Ltd is 8,854 Cr

What are the key factors driving the stock performance of Alivus Life Sciences Ltd and Procter & Gamble Health Ltd?

The stock performance of Alivus Life Sciences Ltd and Procter & Gamble Health Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Alivus Life Sciences Ltd and Procter & Gamble Health Ltd?

As of May 6, 2026, the Alivus Life Sciences Ltd stock price is INR ₹1123.45. On the other hand, Procter & Gamble Health Ltd stock price is INR ₹5334.05.

How do dividend payouts of Alivus Life Sciences Ltd and Procter & Gamble Health Ltd compare?

To compare the dividend payouts of Alivus Life Sciences Ltd and Procter & Gamble Health Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.